Comparative Pharmacology
Head-to-head clinical analysis: INDERAL versus TIMOLOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INDERAL versus TIMOLOL.
INDERAL vs TIMOLOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonselective beta-adrenergic receptor antagonist; competes with catecholamines for binding at beta-1 and beta-2 receptors, decreasing heart rate, myocardial contractility, and blood pressure.
Nonselective beta-adrenergic receptor antagonist (beta-blocker) that competively blocks beta-1 and beta-2 receptors, reducing heart rate, contractility, and cardiac output. In glaucoma, decreases intraocular pressure by reducing aqueous humor production.
Hypertension: 40 mg orally twice daily; increase as needed up to 640 mg/day. Angina: 80-320 mg orally daily in divided doses. Migraine prophylaxis: 80 mg orally daily in divided doses; up to 160-240 mg/day. Arrhythmias: 10-30 mg orally 3-4 times daily. IV: 1-3 mg IV bolus at 1 mg/min; may repeat after 2 min.
0.25-0.5 mg ophthalmic solution instilled twice daily; for oral: 10-20 mg twice daily.
None Documented
None Documented
Clinical Note
moderateTimolol + Digoxin
"Timolol may increase the bradycardic activities of Digoxin."
Clinical Note
moderateTimolol + Digitoxin
"Timolol may increase the bradycardic activities of Digitoxin."
Clinical Note
moderateTimolol + Deslanoside
"Timolol may increase the bradycardic activities of Deslanoside."
Clinical Note
moderateTimolol + Acetyldigitoxin
"Timolol may increase the bradycardic activities of Acetyldigitoxin."
3-6 hours (terminal). Clinical context: half-life increases with chronic dosing due to saturable hepatic metabolism; in cirrhosis, half-life may be prolonged to 10-23 hours.
Terminal half-life: 4-5 hours (healthy adults); prolonged to 7-10 hours in renal impairment, 11-16 hours in hepatic impairment; clinical context: once-daily dosing for hypertension/glaucoma.
Renal: 96-99% as metabolites (active 4-hydroxypropranolol and conjugates), <1% unchanged. Biliary/fecal: minimal.
Renal: ~20% unchanged; hepatic metabolism accounts for ~80%, with metabolites excreted renally; minor biliary/fecal elimination (<5%).
Category C
Category A/B
Beta-Blocker
Beta-Blocker